Skip to main navigation
Skip to search
Skip to main content
UNT Health Home
Search content at UNT Health
Home
Research units
Profiles
Publications
Sponsored Projects
Core Facilities
Current state of Alzheimer’s fluid biomarkers
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Current state of Alzheimer’s fluid biomarkers'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Alzheimer
100%
Fluid Biomarkers
100%
Alzheimer's Disease
80%
Clinical Trials
40%
Alzheimer's Disease Pathology
20%
Mechanism of Action
20%
Progressive Neurodegeneration
20%
Cerebrospinal Fluid
20%
Total tau
20%
Pathogenic Mechanism
20%
Triggering Receptor Expressed on Myeloid Cells 2 (TREM2)
20%
Ferritin
20%
Alzheimer's Disease Biomarkers
20%
Cerebrospinal Fluid Biomarkers
20%
Drug Development
20%
Sporadic Alzheimer's Disease
20%
Disease States
20%
Phosphorylated tau
20%
Adverse Reactions
20%
Personalized Medicine
20%
Patient Selection
20%
Diagnostic Utility
20%
YKL-40
20%
Alzheimer's Disease Diagnosis
20%
Context of Use
20%
Synaptotagmin
20%
Alpha-synuclein (α-syn)
20%
SNAP-25
20%
Neurofilament Light (NF-L)
20%
Disease-modifying Therapy
20%
β-site APP-cleaving Enzyme 1 (BACE1)
20%
Alzheimer's Disease Treatment
20%
Disease Pathophysiology
20%
Heterogeneous Pathophysiology
20%
TAR DNA-binding Protein 43 (TDP-43)
20%
Monitoring Efficacy
20%
IP-10
20%
Drug Development Program
20%
Effective Compounds
20%
Neurogranin
20%
Prognosis Assessment
20%
Drug Response Monitoring
20%
VILIP-1
20%
Dose Optimization
20%
Living with
20%
Subject Selection
20%
Biochemistry, Genetics and Molecular Biology
Clinical Trial
100%
Tau
100%
Drug Development
100%
TREM2
50%
Transactive Response Dna Binding Protein-43
50%
Neurogranin
50%
Drug Response
50%
Synaptotagmin
50%
Ferritin
50%
Neurofilament Light
50%
Synuclein
50%
Medicine and Dentistry
Biological Marker
100%
Alzheimer's Disease
87%
Clinical Trial
25%
Tau
25%
Pathophysiology
25%
Cerebrospinal Fluid
25%
Degenerative Disease
12%
Adverse Event
12%
Combination Therapy
12%
Personalized Medicine
12%
Patient Selection
12%
Alzheimer's Disease Biomarkers
12%
Drug Response
12%
Ferritin
12%
Disease Modifying Therapy
12%
Synaptosomal Associated Protein 25
12%
Transactive Response Dna Binding Protein-43
12%
Neurogranin
12%
Synaptotagmin
12%
Diseases
12%
Synuclein
12%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
100%
Alzheimer's Disease
88%
Clinical Trial
22%
Pathophysiology
22%
Drug Development
22%
Diseases
22%
Adverse Event
11%
Degenerative Disease
11%
Synuclein
11%
Synaptotagmin
11%
Synaptosomal Associated Protein 25
11%
Ferritin
11%
Neurogranin
11%
Material Science
Ferritin
50%
Transactive Response Dna Binding Protein-43
50%